Search Results - "Heitmann JS"

B7-H3 membranous expression correlates with histological grading in a two-center cohort of 133 pre-treatment bone and soft tissue sarcoma samples.

Authors: Kloker LD Rottscholl R Heitmann JS et al.

Source: BMC cancer [BMC Cancer] 2026 Jun 06; Vol. 26 (1). Date of Electronic Publication: 2026 Jun 06.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment.

Authors: Ott JM Gassenmaier V Bitzer M et al.

Source: Pathology oncology research : POR [Pathol Oncol Res] 2025 Aug 13; Vol. 31, pp. 1612186. Date of Electronic Publication: 2025 Aug 13 (Print Publication: 2025).

Publication Type: Clinical Trial, Phase I; Journal Article

Journal Info: Publisher: Frontiers Media S. A Country of Publication: Switzerland NLM ID: 9706087 Publication Model: eCollection Cited Medium: Internet ISSN: 1532-2807 (Electronic) Linking ISSN: 12194956 NLM ISO Abbreviation: Pathol Oncol Res Subsets: MEDLINE

B7-H3 (CD276) as Target for T Cell-Based Bispecific Antibody Therapy of Penile Cancer.

Authors: Kielbik A Bahlinger V Schürch CM et al.

Source: ImmunoTargets and therapy [Immunotargets Ther] 2026 May 01; Vol. 15, pp. 577364. Date of Electronic Publication: 2026 May 01 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101606565 Publication Model: eCollection Cited Medium: Print ISSN: 2253-1556 (Print) Linking ISSN: 22531556 NLM ISO Abbreviation: Immunotargets Ther Subsets: PubMed not MEDLINE

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Authors: Marconato M Hackenbruch C Jäger S et al.

Source: Clinical therapeutics [Clin Ther] 2026 Mar; Vol. 48 (3), pp. 232-239. Date of Electronic Publication: 2026 Feb 07.

Publication Type: Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Excerpta Medica Country of Publication: United States NLM ID: 7706726 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-114X (Electronic) Linking ISSN: 01492918 NLM ISO Abbreviation: Clin Ther Subsets: MEDLINE

CLEC12A-directed immunocytokine with target cell-restricted IL-15 activity for treatment of acute myeloid leukemia.

Authors: Klimovich B Anton L Jung J et al.

Source: Frontiers in immunology [Front Immunol] 2025 Mar 27; Vol. 16, pp. 1561823. Date of Electronic Publication: 2025 Mar 27 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Personalised multipeptide-based T-cell activator for chronic lymphocytic leukaemia: an open-label, single-centre, phase 1 study.

Authors: Heitmann JS Maringer Y Jung S et al.

Source: The Lancet. Haematology [Lancet Haematol] 2026 Feb; Vol. 13 (2), pp. e74-e85. Date of Electronic Publication: 2026 Jan 14.

Publication Type: Journal Article; Clinical Trial, Phase I

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE

Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.

Authors: Heitmann JS Jung S Wacker M et al.

Source: Frontiers in immunology [Front Immunol] 2024 Nov 26; Vol. 15, pp. 1482715. Date of Electronic Publication: 2024 Nov 26 (Print Publication: 2024).

Publication Type: Journal Article; Clinical Trial, Phase II

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.

Authors: Jung S Nelde A Maringer Y et al.

Source: Frontiers in oncology [Front Oncol] 2024 Oct 14; Vol. 14, pp. 1458449. Date of Electronic Publication: 2024 Oct 14 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens.

Authors: Englisch A Hayn C Jung S et al.

Source: Frontiers in oncology [Front Oncol] 2024 Aug 26; Vol. 14, pp. 1441625. Date of Electronic Publication: 2024 Aug 26 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Induction of NK cell reactivity against acute myeloid leukemia by Fc-optimized CD276 (B7-H3) antibody.

Authors: Stefańczyk SA Hagelstein I Lutz MS et al.

Source: Blood cancer journal [Blood Cancer J] 2024 Apr 18; Vol. 14 (1), pp. 67. Date of Electronic Publication: 2024 Apr 18.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.

Authors: Hackenbruch C Bauer J Heitmann JS et al.

Source: Frontiers in oncology [Front Oncol] 2024 Mar 28; Vol. 14, pp. 1367450. Date of Electronic Publication: 2024 Mar 28 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Protocol of a first-in-human clinical trial to evaluate the safety, tolerability, and preliminary efficacy of the bispecific CD276xCD3 antibody CC-3 in patients with colorectal cancer (CoRe_CC-3).

Authors: Jung S Schlenk RF Hackenbruch C et al.

Source: Frontiers in oncology [Front Oncol] 2024 Feb 12; Vol. 14, pp. 1351901. Date of Electronic Publication: 2024 Feb 12 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification.

Authors: Hoenisch Gravel N Nelde A Bauer J et al.

Source: Nature communications [Nat Commun] 2023 Nov 17; Vol. 14 (1), pp. 7472. Date of Electronic Publication: 2023 Nov 17.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.

Authors: Heitmann JS Tandler C Marconato M et al.

Source: Nature communications [Nat Commun] 2023 Aug 18; Vol. 14 (1), pp. 5032. Date of Electronic Publication: 2023 Aug 18.

Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.

Authors: Heitmann JS Schlenk RF Dörfel D et al.

Source: Journal of hematology & oncology [J Hematol Oncol] 2023 Aug 17; Vol. 16 (1), pp. 96. Date of Electronic Publication: 2023 Aug 17.

Publication Type: Multicenter Study; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE

PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development.

Authors: Lemke S Dubbelaar ML Zimmermann P et al.

Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Apr 15; Vol. 13 (4). Date of Electronic Publication: 2025 Apr 15.

Publication Type: Journal Article

Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.

Authors: Lutz MS Zekri L Weßling L et al.

Source: Frontiers in immunology [Front Immunol] 2023 Apr 14; Vol. 14, pp. 1163136. Date of Electronic Publication: 2023 Apr 14 (Print Publication: 2023).

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.

Authors: Labrenz J Edelmann D Heitmann JS et al.

Source: Pharmaceutical statistics [Pharm Stat] 2023 Mar; Vol. 22 (2), pp. 236-247. Date of Electronic Publication: 2022 Oct 25.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 101201192 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1539-1612 (Electronic) Linking ISSN: 15391604 NLM ISO Abbreviation: Pharm Stat Subsets: MEDLINE

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.

Authors: Bauer J Köhler N Maringer Y et al.

Source: Nature communications [Nat Commun] 2022 Oct 27; Vol. 13 (1), pp. 6401. Date of Electronic Publication: 2022 Oct 27.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.

Authors: Kauer J Märklin M Pflügler M et al.

Source: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Oct; Vol. 148 (10), pp. 2759-2771. Date of Electronic Publication: 2022 May 13.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 7902060 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1335 (Electronic) Linking ISSN: 01715216 NLM ISO Abbreviation: J Cancer Res Clin Oncol Subsets: MEDLINE